Skip to main content
. 2022 Apr;11(4):607–616. doi: 10.21037/tlcr-22-171

Figure 1.

Figure 1

Flowchart of participant selection in the training set (A) and in the testing set (B). LC, lung cancer; ICI, immune checkpoint inhibitor; CT, computed tomography; HPD, hyperprogressive disease.